Table 2 MYC inhibitors in clinical development
From: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Inhibitor | Pharmaceutical company | Mechanism | Indication | Clinical Trial | Trial identifier |
|---|---|---|---|---|---|
OMO-103 | Peptomyc S.L. | MYC dominant negative | Advanced Solid Tumors | Phase I/IIa; Monotherapy | NCT04808362 |
PDAC | Phase Ib; Combination with Gemcitabine/Nab-paclitaxel in PDAC | NCT06059001 | |||
IDP-121 | IDP Pharma | c-MYC degradation | Hematologic malignancies | Phase I/II; Monotherapy | NCT05908409 |
WBC100 | Zhejiang University | c-MYC degradation | Advanced Solid Tumors | Phase I; Monotherapy | NCT05100251 |
OTX-2002 | OMEGA Therapeutics | MYC epigenomic modulation | HCC; Solid tumors | Phase I/II; Monotherapy and in combination with SoC in HCC | NCT05497453 |
